Apellis Pharmaceuticals CEO Cedric Francois' 2021 pay slips 2% to $9.1M
Apellis Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 20, 2022
Apellis Pharmaceuticals reported fiscal year 2021 executive compensation information on April 20, 2022.
In 2021, five executives at Apellis Pharmaceuticals received on average a compensation package of $4M, a 7% decrease compared to previous year.
Average pay of disclosed executives at Apellis Pharmaceuticals
Cedric Francois, Chief Executive Officer, received $9.1M in total, which decreased by 2% compared to 2020. 71% of Francois' compensation, or $6.5M, was in option awards. Francois also received $312K in bonus, $647K in salary, $1.7M in stock awards, as well as $10K in other compensation.
For fiscal year 2021, the median employee pay was $321,867 at Apellis Pharmaceuticals. Therefore, the ratio of Cedric Francois' pay to the median employee pay was 28 to one.
Timothy Sullivan, Chief Financial Officer, received a compensation package of $3.1M, which decreased by 12% compared to previous year. 63% of the compensation package, or $1.9M, was in option awards.
Pascal Deschatelets, Chief Scientific Officer, earned $2.6M in 2021, a 9% decrease compared to previous year.
Adam Townsend, Chief Commercial Officer, received $2.6M in 2021, which decreases by 9% compared to 2020.
Federico Grossi, Chief Medical Officer, earned $2.6M in 2021.
Related executives
Cedric Francois
Apellis Pharmaceuticals
Chief Executive Officer
Timothy Sullivan
Apellis Pharmaceuticals
Chief Financial Officer
Pascal Deschatelets
Apellis Pharmaceuticals
Chief Scientific Officer
Federico Grossi
Apellis Pharmaceuticals
Chief Medical Officer
Adam Townsend
Apellis Pharmaceuticals
Chief Commercial Officer
You may also like
Source: SEC filing on April 20, 2022.